Pitavastatin



Pitavastatin





(pih ta’ vah sta’ tin)

Livalo

PREGNANCY CATEGORY X


Drug Classes

Antihyperlipidemic

HMG-CoA reductase inhibitor


Therapeutic Actions

Inhibits HMG-CoA reductase, the enzyme that catalyzes the first step in the cholesterol synthesis pathway, resulting in a decrease in serum cholesterol, serum LDLs (associated with increased risk of CAD), and increased serum HDLs (associated with decreased CAD risk); increases hepatic LDL recapture sites and enhances reuptake and catabolism of LDL; lowers triglyceride levels.


Indications



  • As adjunctive therapy to exercise and diet to reduce elevated total cholesterol, LDLs, apolipoprotein B, and triglycerides and increase HDL in patients with primary hyperlipidemia and mixed dyslipidemia



Available Forms

Tablets—1, 2, 4 mg


Dosages

Adults

Starting dosage, 2 mg/day PO; may increase to a maximum of 4 mg/day.

Pediatric patients

Safety and efficacy not established.

Patients with moderate to end-stage renal impairment on hemodialysis

1 mg/day PO; maximum dosage is 2 mg/day.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Pitavastatin

Full access? Get Clinical Tree

Get Clinical Tree app for offline access